Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications Pharmaceutical TechnologyThe FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Technology The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. Oncology Read full story Post navigation Previous: Arna Pharma and Slate Run complete JV for new US companyNext: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026